Daratumumab: ANMAT-approved alternative for certain cancers

National Agency for Medicines, Food and Medical Technology (ANMAT) Authorized for use of daratumumab For multiple myeloma patients I have no intention of undergoing a bone marrow transplant.. The authorization is Results of the international phase 3 CEPHEUS trial It tested the efficacy of adding daratumumab to standard chemotherapy treatment. they were studied over 700 patients And the results showed a very optimistic outlook. No myeloma cells were detected in 6 of 10 patients Using the most sensitive tests, 48.7% achieved EMR (Minor residual disease) negative, In other words, it is No new cells detected for over 1 yearwhile 26.3% did not use daratumumab.
In an additional 19.6% of patients, the new drug was able to remove traces of myelin and extend the time the disease did not progress.

They found that the most cooperative mammalian species had far fewer cases of cancer

he multiple myeloma It is a type of cancer, so found in the blood And its origin is myeloid forming cells They multiply uncontrollably and produce antibodies that are counterproductive to the immune system because they affect the production of red blood cells, white blood cells, and platelets. may lead to serious problems such as kidney failure, anemia, and bone fractures; and other infectious diseases.
in argentina This announcement gives patients with multiple myeloma confidence as they look once again at the limited treatments they have been receiving. They will have access to things that will give them better results. In Japan, approximately 1300 cases per year in people aged 50 to 70.

What is daratumumab?
Daratumumab is a monoclonal antibody directed against: attacks a protein on myeloma cells called CD38, Its method of action is based on the destruction of multiple myeloma cells through a combination of immune system activation and direct cytotoxic effects.